Table 1.

Clinical and pathological characteristics according to KMT2C gene mutation status (n =27)

	KMT2C Wild-type (n=16)	KMT2C Mutation (n=11)	p-value
Gender n (%), Male	4 (25.0)	7 (63.6)	0.401
Female	12 (75.0)	4 (36.4)
Age (yrs), mean ± SD	58.4 ± 13.4	63.2 ± 15.3	0.061
Race, n (%), Caucasian	9 (56.2)	6 (54.5)	0.167
African-American	0 (0.0)	1 (9.1)
Hispanic	0 (0.0)	2 (18.2)
Asian	6 (37.5)	1 (9.1)
Unknown	1 (6.2)	1 (9.1)
T stage, 1	1 (6.2)	2 (18.2)	0.246
2	1 (6.2)	3 (27.3)
3	7 (43.8)	2 (18.2)
4	7 (43.8)	4 (36.4)
N stage, 0	8 (50.0)	5 (45.5)	0.390
1	2 (12.5)	2 (18.2)
2	3 (18.8)	0 (0.0)
3	3 (18.8)	4 (36.4)
TNM stage, I	1 (6.2)	4 (36.4)	0.060
II	9 (56.2)	2 (18.2)
III	6 (37.5)	5 (45.5)
Neoadjuvant treatment, None	10 (62.5)	7 (63.6)	0.691
Chemotherapy	5 (31.2)	4 (36.4)
Chemotherapy and radiation therapy	1 (6.2)	0 (0.0)
Adjuvant treatment, None	7 (43.8)	9 (81.8)	0.118
Chemotherapy	6 (37.5)	2 (18.2)
Chemotherapy and radiation therapy	3 (18.8)	0 (0.0)
Recurrence, No	11 (68.8)	6 (54.5)	0.754
Yes	3 (18.8)	3 (27.3)
Unknown	2 (12.5)	2 (18.2)
H. pylori infection at diagnosis, No	7 (43.8)	4 (36.4)	0.912
Yes	8 (50.0)	6 (54.5)
Unknown	1 (6.3)	1 (9.1)
Atrophic gastritis or intestinal metaplasia, No	11 (68.8)	0 (0.0)	0.001
Yes	5 (31.3)	9 (81.8)
Unknown	0 (0.0)	2 (18.2)

H. pylori, Helicobacter pylori